Abstract 6002
Background
Although cancer patients are known to be at higher risk of infection and its subsequent complications, the magnitude of infection-related mortality in cancer patients remains unknown. In this study, data from Surveillance, Epidemiology, and End Results Program (SEER) were explored in order to identify how far infection was identified as the cause of death in cancer patients in the United States between 2010 and 2016.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2018 Submission) was used as the data source. Only cases with malignant behavior, known age, and those in research database were included. Analysis was made for patients who were diagnosed between 2010 and 2016 whose vital status was reported as "dead" at the time of study cut-off. Data about cause of death were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25.
Results
1,012,769 cases were included in the final data analysis. Infection was identified as the cause of death in 1.89% of cases (n = 19,155). Infection-related mortality was much higher in patients diagnosed with hematological malignancies (3.6%, n = 3,472) compared with non-hematological malignant diseases (1.7%, n = 15683). Deaths related to infection were also higher in males (2.2%, n = 11,827) compared with females (1.6%, n = 7,328).
Conclusions
Although infection is perceived as a major cause of morbidity and mortality in cancer patients, its current magnitude may be lower than expectations. Infection-related mortality showed higher prevelance in males and in patients with hematological malignancies.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract